BofA analyst Tazeen Ahmad downgraded Sage Therapeutics to Neutral from Buy with a price target of $25, down from $66.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- Sage Therapeutics downgraded to Hold from Buy at Stifel
- American downgraded, United upgraded: Wall Street’s top analyst calls
- Sage (NASDAQ:SAGE) Plummets On FDA Snub for Zuranolone in Major Depression Disorder
- Biogen price target lowered to $290 from $310 at BofA
- Biogen price target lowered to $269 from $276 at Wedbush